Artios Pharma Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Artios Pharma Limited - overview
Established
2016
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
Based in Cambridge, UK, and founded in 2016, Artios Pharma Limited is a developer of novel cancer treatments designed to target DNA Damage Response (DDR). In November 2025, Artios Pharma Limited raised GBP 87. 3 million in series D funding co-led by SV Health Investors, RA Capital Management, with participation from Janus Henderson Investors, IP Group , Sofinnova Partners, Schroders Capital, Piper Heartland Healthcare Capital, Pfizer Venture Investments, Andera Partners, Avidity Partners, EQT Life Sciences, Invus [DUP], M Ventures, Novartis Venture Fund, and Omega Funds. Michael T.
Andriole is the current CEO. The company's medications center on creating treatments through deoxyribonucleic corrosive harm reaction (DDR) pathways to assist changes to their DNA so that it can advance, empowering doctors to specifically slaughter cancer cells through a concept known as manufactured lethality. The company plans to use the November 2025 funding to advance late-stage trials and progress its DDR ADC program.
Current Investors
SV Health Investors, M Ventures, Touchstone Innovations
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.artios.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
Artios Pharma Limited - timeline of key events
Artios Pharma Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.